We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Simple Colorimetric Assay Determines Human Mercaptalbumin Concentration

By LabMedica International staff writers
Posted on 30 Jun 2022
Print article
Image: VICTOR Nivo Multimode Microplate Reader (Photo courtesy of PerkinElmer)
Image: VICTOR Nivo Multimode Microplate Reader (Photo courtesy of PerkinElmer)

Human serum albumin (HAS) can take on two forms, mercaptalbumin (HMA) or non-mercaptalbumin (HNA), depending on the redox status of its Cys34. The ratio of HMA and HNA is considered to be a novel biomarker of oxidative stress.

The majority of studies on the redox state of HSA utilize high performance liquid chromatography (HPLC). Several recent studies have also employed mass spectrometry, which yields a higher resolution, thus allowing for finer distinctions between molecular structures. A handful of studies have explored alternative approaches using simple dye-based assays.

Clinical Laboratorians at The University of Tokyo Hospital (Tokyo, Japan) collaborated with colleagues at Nitto Boseki Co. Ltd., (Kawasaki, Japan) measured the concentrations of HMA in serum samples from 36 healthy subjects based on absorption changes of Michler's Hydrol. Michler's Hydrol (4,4′-Bis(dimethylamino)benzhydrol) is a blue dye with a maximum absorption at 612 nm, and its absorption decreases when it reacts with a thiol group.

After processing the samples, the solution was incubated further at room temperature for 20 minutes and absorbance at 612 nm (A612) was measured by a 96-well plate Nivo 3F microplate reader (PerkinElmer, Waltham, MA, USA). To evaluate the performance of the assays, the correlation was determined by a linear regression between the HMA concentrations obtained by Michler's Hydrol assay and corresponding reference concentrations obtained by HPLC and Bromocresol purple (BCP) assays.

The scientists reported that HMA concentrations obtained by Michler's Hydrol assay were highly correlated (r2 = 0.97) with reference values obtained by HPLC (HMA %) and BCP assay (total albumin). The HNA% obtained by Michler's Hydrol and BCP assays combined also gave a good correlation (r2 = 0.96) and a small deviation (average 2.4%) with respect to HPLC as a reference method. The use of the HMA/HNA ratio, which is a function of oxidation of Cys34, is considered a potential biomarker to assess the severity of chronic diseases for which oxidative stress is a significant etiological manifestation.

The authors concluded that the concentrations of HMA in human serum can be measured by Michler's Hydrol assay, which is based on an approximation of HMA concentrations with Michler's Hydrol's colorimetric changes mainly due to thiols. The assay accuracy was significantly improved by pre-incubation of a subset of the samples with an alkylating agent (iodoacetamide) and subtracting their absorption from the absorption of corresponding samples without alkylation. Proportions of HMA and HNA were also obtained by combining Michler's Hydrol assay and the BCP assay (for total albumin concentration). The results correlated well with HPLC, which has been established as a standard method for HMA/HNA measurement. The study was published on June 8, 2022 in the journal Practical Laboratory Medicine.

Related Links:
The University of Tokyo Hospital
Nitto Boseki Co. Ltd
PerkinElmer

 

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.